Zhejiang Huode Biotechnology Co., Ltd. (Hopstem) was established in Hangzhou in January 2017 by a group of neuroscience and stem cell scientists of Johns Hopkins University. Hopstem has established world-leading human iPSCs/ESCs neural differentiation and cell engineering technology platform and finished serial A financing.The company has 1,400 square meters of GLP/GMP cell manufactory and R&D center in Hangzhou. Hopstem provides high-quality human cells, reagents and services, including various types of human neural cells, 3D brain organoids, maturation medium and gene editing, etc. These human cells and organoids can be used as disease models or material for research, drug screening and toxicity tests. Hopstem Biotechnology aims to develop the most advanced cell therapies for neurological diseases, including human neuronal precursor cells for treatment of stroke, traumatic brain injury, cerebral palsy and other pipelines.